Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.32 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL870518 | 0.95 | TACR1 (0.32) | P2RX1P2RX4P2RX7P2RX3TACR1 | |
| SCHEMBL10072326 | 0.94 | HDAC3 (0.32) | P2RX1P2RX4P2RX7P2RX3TACR1 | |
| SCHEMBL870231 | 0.90 | HPGD (0.32) | P2RX7POLB | |
| SCHEMBL871534 | 0.90 | HPGD (0.31) | P2RX7POLB | |
| SCHEMBL883221 | 0.90 | HPGD (0.31) | P2RX7POLB | |
| SCHEMBL3107706 | 0.89 | TACR1 (0.38) | P2RX1P2RX4P2RX7P2RX3TACR1 | |
| SCHEMBL870579 | 0.89 | MEN1 (0.36) | P2RX1P2RX4P2RX7P2RX3TACR1 | |
| SCHEMBL869684 | 0.88 | PPARG (0.32) | P2RX7 | |
| SCHEMBL10083433 | 0.88 | TACR1 (0.33) | P2RX1P2RX4P2RX7P2RX3TACR1 | |
| SCHEMBL870589 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619189-B1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | P2RX1 287/4885P2RX4 464/4885P2RX7 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.